AMLo Biosciences

AMLo Biosciences is a private, pre-revenue diagnostics company developing innovative prognostic tests to better stratify cancer patients by their individual risk of disease progression. Its lead program targets early-stage melanoma, where over 90% of patients are currently over-treated, aiming to redirect resources to high-risk individuals and generate significant healthcare savings. Founded by a team with strong oncology and biotech experience, the company has secured £6.4 million in combined research and equity funding to advance its pipeline, which also includes tests for cutaneous squamous cell carcinoma (cSCC) and oropharyngeal squamous cell carcinoma (OPSCC).

Platform for discovering and validating protein-based or molecular biomarkers that predict cancer progression risk, designed for integration into standard pathology workflows.

AMLo competes in the cancer prognostic space, facing potential competition from other biomarker-driven tests (e.g., gene expression profiles) and existing clinical-pathological risk models. Its success will depend on demonstrating superior accuracy, cost-effectiveness, and ease of integration compared to existing standards of care and emerging alternatives.